I'm really bullish on BDTX right now. With a strong cash position and a major deal completed, I'm convinced this stock is undervalued at $1.5. The pot...
Read
More
I'm really bullish on BDTX right now. With a strong cash position and a major deal completed, I'm convinced this stock is undervalued at $1.5. The potential FDA approval and pipeline are looking solid, and I believe it could return to the secondary offering price of $5 soon.
I'm confident that BDTX is set for a significant price increase based on Raymond James' bullish outlook. With a target price of $20 and strong analyst...
Read
More
I'm confident that BDTX is set for a significant price increase based on Raymond James' bullish outlook. With a target price of $20 and strong analyst support, the upside potential is hard to ignore, especially given the upcoming clinical updates that could drive the stock even higher.